← All candidates
18 insider filings on record.
18 filings on record.
HBIOHARVARD BIOSCIENCE INC
NasdaqCM · Healthcare · $27.69M
$8.04
-1.11% · Sep 15
18 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · dailyNo open-market activity in range
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what HBIO ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$27.69M
Float
3.5M
78% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
14.0
Price / sales
0.3
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
13 more transactions on Pro →Context
Wall St
$6.00 avg target
-25.4% vs today · 1 analyst
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 3 quarters beat
Q4 '25$0.00 act−$0.35
Q3 '25$0.00 act−$0.05
Q2 '25−$0.10 act+$0.15
Coverage
Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New ...GuruFocus.com · 05-12Harvard Bioscience, Inc. Q1 2026 Earnings Call SummaryMoby · 05-12How The Harvard Bioscience (HBIO) Investment Narrative Is Resetting After Lower 2026 ExpectationsSimply Wall St. · 03-16Harvard Bioscience Inc (HBIO) Q4 2025 Earnings Call Highlights: Strong Operational Efficiency ...GuruFocus.com · 03-12
The file stays open
18 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice